Please wait...
| ID | PMID | YEAR | Sequence | Name | Length | Linear/Cyclic | Chirality | Chem-MOD | C-ter MOD | N-ter MOD | Nature | Origin | Cell Line | Cancer Type | Assay | Activity | Testing Time | Tissue Affected | Patents |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37344820 | 2023 | Moricin | 43 | Linear | L | None | Free | Free | Antimicrobial | Bombyx mori | MDA-MB-231 | Triple-negative Breast Cancer | Trypan blue assay | 70% cell viability at 6.25 µg/ml | 24-h | Breast | None | ||
| 37344820 | 2023 | Moricin | 43 | Linear | L | None | Free | Free | Antimicrobial | Bombyx mori | MDA-MB-231 | Triple-negative Breast Cancer | LDH release assay | Significant decrease in cell viability at 6.25 μg/ml | 24-h | Breast | None | ||
| 37344820 | 2023 | Moricin | 43 | Linear | L | None | Free | Free | Antimicrobial | Bombyx mori | MDA-MB-231 | Triple-negative Breast Cancer | MTT assay | 70% cell viability at 6.25 µg/ml | 24-h | Breast | None | ||
| 35628312 | 2022 | rScyreprocin | 90 | Linear | L | None | His-Tag | Free | Antimicrobial | Recombinant product of Scyreprocin | HeLa | Cervical cancer | MTS assay | IC50 = 3.34 x 104 µM | 24-h | Cervix | None | ||
| 35628312 | 2022 | rScyreprocin | 90 | Linear | L | None | His-Tag | Free | Antimicrobial | Recombinant product of Scyreprocin | DU-145 | Prostate cancer | MTS assay | IC50 = 1158.30 µM | 24-h | Prostate | None | ||
| 35628312 | 2022 | rScyreprocin | 90 | Linear | L | None | His-Tag | Free | Antimicrobial | Recombinant product of Scyreprocin | T-24 | Urinary Bladder Cancer | MTS assay | IC50 = 1.94 x 105 µM | 24-h | Bladder | None | ||
| 35628312 | 2022 | rScyreprocin | 90 | Linear | L | None | His-Tag | Free | Antimicrobial | Recombinant product of Scyreprocin | HepG-2 | Liver Cancer | MTS assay | IC50 = 441.01 µM | 24-h | Liver | None | ||
| 35628312 | 2022 | rScyreprocin | 90 | Linear | L | None | His-Tag | Free | Antimicrobial | Recombinant product of Scyreprocin | H-460 | Lung Cancer | MTS assay | IC50 = 6.27 µM | 72-h | Lung | None | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | PC-3 | Prostate Cancer | Resazurin dye assay | IC50 = 1.84 ± 0.17 µM | 48-h | Prostate | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | MNT-1 | Skin Cancer | Resazurin dye assay | IC50 = 2.24 ± 0.05 µM | 48-h | Skin | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | A-2780 | Ovarian Cancer | Resazurin dye assay | IC50 = 2.31 ± 0.08 µM | 48-h | Ovary | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | MiaPaCa.2 | Pancreatic Cancer | Resazurin dye assay | IC50 = 6.94 ± 0.27 µM | 48-h | Pancreas | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | A-549 | Lung Cancer | Resazurin dye assay | IC50 = 3.74 ± 3.46 µM | 48-h | Lung | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | MCF-7 | Breast Cancer | Resazurin dye assay | IC50 = 3.77 ± 0.12 µM | 48-h | Breast | US_10550155_B2 | ||
| 35740895 | 2022 | [G10a]3-SHa | 41 | Linear | Mix | None | Amidation | Free | Antimicrobial and Anticancer | Analog of temporin SHa | HepG-2 | Liver Cancer | Resazurin dye assay | IC50 = 5.49 ± 0.37 µM | 48-h | Liver | US_10550155_B2 | ||
| 34449322 | 2021 | rhCGA-N46 | 46 | Linear | L | None | Free | Free | Antimicrobial | Found in neurons and endocrine cells in Humans | HCT-116 | Colon Cancer | MTT assay | IC50 = 1.997 µg/ml | 24-h | Colon | None | ||
| 31947688 | 2020 | Lunasin | 44 | Linear | L | None | Free | Free | Anticancer | Soybean | HCT-116 | Colon Cancer | MTT assay | IC50 = 107.5 ± 1.9 μM | 72-h | Colon | None | ||
| 32562730 | 2020 | rCT-II | 60 | Cyclic(C3-C21,C14-C38,C42-C53,C54-C59) | L | None | Free | Free | Anticancer | Naja naja | MCF-7 | Breast Cancer | MTT assay | IC50 = 3.66 µg/mL | 24-h | Breast | None | ||
| 32836586 | 2020 | Mambalgin-1 | 57 | Linear | L | None | Free | Free | Anticancer | Dendroaspis polylepsis | MCF-7 | Breast Cancer | MTT assay | 22.43% cytotoxicity at 10 µg/mL | 48-h | Breast | None | ||
| 31233771 | 2019 | Nubein6.8 | 60 | Linear | L | None | Free | Free | Anticancer | Naja nubiae | PANC-1 | Pancreatic Cancer | MTT assay | slight toxicity above 3.7 μM | 24-h | Pancreas | None | ||
| 31233771 | 2019 | Nubein6.8 | 60 | Linear | L | None | Free | Free | Anticancer | Naja nubiae | A-2780 | Ovarian Cancer | MTT assay | EC50 = 1.249 ± 0.06 μM | 24-h | Ovary | None | ||
| 31233771 | 2019 | Nubein6.8 | 60 | Linear | L | None | Free | Free | Anticancer | Naja nubiae | A-375 | Skin Cancer | MTT assay | EC50 = 0.54 ± 0.04 μM | 24-h | Skin | None | ||
| 30851450 | 2019 | Ss-arasin | 41 | Linear | L | None | Free | Free | Antimicrobial | Scylla serrata | HT-29 | Colon Cancer | MTT assay | IC50 = 2.9 µM | 24-h | Colon | None | ||
| 30851450 | 2019 | Ss-arasin | 41 | Linear | L | None | Free | Free | Antimicrobial | Scylla serrata | HeLa | Cervical Cancer | MTT assay | IC50 = 3.06 µM | 24-h | Cervix | None | ||
| None | 2019 | SMP43 | 43 | Linear | L | None | Free | Free | Antimicrobial | Scorpio maurus palmatus | KG-1a | Leukemia Cancer | LDH leakage assay | Fig 2 | NA | Blood | None | ||
| None | 2019 | SMP43 | 43 | Linear | L | None | Free | Free | Antimicrobial | Scorpio maurus palmatus | CCRF-CEM | Leukemia Cancer | LDH leakage assay | Fig 2 | NA | Blood | None | ||
| None | 2019 | SMP43 | 43 | Linear | L | None | Free | Free | Antimicrobial | Scorpio maurus palmatus | KG-1a | Leukemia Cancer | CellTiter-Glo assay | LC50 = 16 ± 0.7 µg/mL | 24-h | Blood | None | ||
| None | 2019 | SMP43 | 43 | Linear | L | None | Free | Free | Antimicrobial | Scorpio maurus palmatus | CCRF-CEM | Leukemia Cancer | CellTiter-Glo assay | LC50 = 13 ± 1.5 µg/mL | 24-h | Blood | None | ||
| 29559362 | 2018 | PaDef | 47 | Linear | L | None | Free | Free | Antimicrobial | Persea americana var. drymifolia | K-562 | Blood Cancer | MTT assay | IC50 = 97.3 μg/mL | 24-h | Blood | None | ||
| 29076508 | 2017 | PvD1 | 47 | Linear | L | None | Free | Free | Antimicrobial | Phaseolus vulgaris | MDA-MB-231 | Breast Cancer | MTT assay | IC50 = 0.82 ± 0.14 µM | 24-h | Breast | None | ||
| 29076508 | 2017 | PvD1 | 47 | Linear | L | None | Free | Free | Antimicrobial | Phaseolus vulgaris | HBMEC | Brain Cancer | MTT assay | Not Available | 24-h | Brain | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | H-1299 | Lung Cancer | MTT assay | 80% cytotoxicity 10 μM concentration | 24-h | Lung | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 53 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | HeLa | Cervical Cancer | LDH leakage assay | ~80% LDH release at 15 μM | 12-h | Cervix | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | HeLa | Cervical Cancer | MTT assay | 20% cytotoxicity 5 μM concentration | 24-h | Cervix | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | HT-1080 | Fibrosarcoma | MTT assay | 20% cytotoxicity 5 μM concentration | 24-h | Fibrous connective tissue | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | HEK-293T | Renal Cancer | MTT assay | 20% cytotoxicity 5 μM concentration | 24-h | Renal | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | MCF-7 | Breast Cancer | LDH leakage assay | >80% LDH release at 15 μM | 24-h | Breast | None | ||
| 28422156 | 2017 | Laterosporulin10 (LS10) | 52 | Linear | L | None | Free | Free | Antimicrobial | Brevibacillus sp. strain SKDU10 | MCF-7 | Breast Cancer | MTT assay | 40% cytotoxicity at 5 μM concentration | 24-h | Breast | None | ||
| 28902151 | 2017 | APETx4 | 42 | Linear | L | None | Free | Free | Anticancer | Anthopleura elegantissima | MDA-MB-435S | Skin Cancer | CellTox Green Dye assay | Green object count < 100 /mm2 at 20 μM | 20-h | Skin | None | ||
| 28902151 | 2017 | APETx4 | 42 | Linear | L | None | Free | Free | Anticancer | Anthopleura elegantissima | LNCaP | Prostate Cancer | CellTox Green Dye assay | Green object count = 300 /mm2 at 20 μM | 20-h | Prostate | None | ||
| 28902151 | 2017 | APETx4 | 42 | Linear | L | None | Free | Free | Anticancer | Anthopleura elegantissima | SH-SY5Y | Brain Tumor | CellTox Green Dye assay | Green object count = 400 /mm2 at 20 μM | 20-h | Brain | None | ||
| 27470405 | 2016 | PaDef | 47 | Linear | L | None | Free | Free | Antimicrobial | Persea americana var. drymifolia | MCF-7 | Breast Cancer | Trypan blue assay | IC50 = 141.62 μg/ml | 48-h | Breast | None | ||
| 26657293 | 2016 | HBD-3 | 45 | Linear | L | None | Free | Free | Antimicrobial | Homo sapiens | Jurkat | Blood Cancer | MTT assay | IC50 ~ 15 µM | 48-h | Blood | None | ||
| 26657293 | 2016 | HBD-3 | 45 | Linear | L | None | Free | Free | Antimicrobial | Homo sapiens | HL-60 | Blood Cancer | MTT assay | IC50 ~ 10 µM | 48-h | Blood | None | ||
| 26657293 | 2016 | HBD-3 | 45 | Linear | L | None | Free | Free | Antimicrobial | Homo sapiens | PC-3 | Prostate Cancer | MTT assay | IC50 ~ 22 µM | 48-h | Prostate | None | ||
| 26657293 | 2016 | HBD-3 | 45 | Linear | L | None | Free | Free | Antimicrobial | Homo sapiens | U-937 | Blood Cancer | MTT assay | IC50 ~ 21 µM | 48-h | Blood | None | ||
| 26657293 | 2016 | HBD-3 | 45 | Linear | L | None | Free | Free | Antimicrobial | Homo sapiens | HeLa | Cervical Cancer | MTT assay | IC50 ~ 9 µM | 48-h | Cervix | None | ||
| 27347099 | 2016 | Cecropin XJ | 41 | Linear | L | None | Free | Free | Antimicrobial | Larvae of Bombyx mori | Huh-7 | Liver Cancer | MTT assay | Cell viability = 50% at 50 µmol/l | 24-h | Liver | None | ||
| 27503651 | 2016 | NaD1 | 47 | pseudo cyclic | L | None | Free | Free | Antifungal and Anticancer | Nicotiana alata | U-937 | Blood Cancer | PI uptake assay | 46.4±8.2% cell death at 10 µM | Not Available | Blood | None | ||
| 25802281 | 2015 | TPP3 | 49 | Linear | L | None | Free | Free | Antifungal | pistils from tomato flowers | U-937 | Leukemia Cancer | LDH leakage assay | 35% cytotoxicity at 10 μM | Not Available | Blood | None | ||
| 26527862 | 2015 | TAT-DV1-BH3 | 49 | Linear | Mix | None | Free | Free | Anticancer | Synthetic polypeptide | MDA-MB-231 | Breast cancer | CCK-8 assay | Survival rate = 28.67±8.22% at 80 µM | 72-h | Breast | None | ||
| 26527862 | 2015 | TAT-DV1-BH3 | 49 | Linear | Mix | None | Free | Free | Anticancer | Synthetic polypeptide | MCF-7 | Breast cancer | CCK-8 assay | Survival rate = 36.97±4.22% at 80 µM | 72-h | Breast | None | ||
| 25802281 | 2015 | TPP3 | 49 | Linear | L | None | Free | Free | Antifungal | pistils from tomato flowers | U-937 | Leukemia Cancer | PI uptake assay | 69.6% cell death at 10 μM | Not Available | Blood | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HL-60 | Leukemia Cancer | LDH leakage assay | IC50 = 23.01 μg/mL | 24-h | Blood | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | DU-145 | Prostrate Cancer | LDH leakage assay | IC50 = 15.91 μg/mL | 24-h | Prostate | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HepG-2 | Liver Cancer | LDH leakage assay | IC50 = 28.99 μg/mL | 24-h | Liver | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | MCF-7 | Breast Cancer | LDH leakage assay | IC50 = 23.9 μg/mL | 24-h | Breast | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HL-60 | Leukemia Cancer | MTT assay | IC50 < 20 μg/mL | 24-h | Blood | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | DU-145 | Prostrate Cancer | MTT assay | IC50 ~ 15 μg/mL | 24-h | Prostate | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HepG-2 | Liver Cancer | MTT assay | IC50 ~ 20 μg/mL | 24-h | Liver | None | ||
| 26482932 | 2015 | Cytotoxin-II | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | MCF-7 | Breast Cancer | MTT assay | IC50 ~ 10 μg/mL | 24-h | Breast | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HL-60 | Leukemia Cancer | LDH leakage assay | IC50 = 38.3 μg/mL | 24-h | Blood | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | DU-145 | Prostrate Cancer | LDH leakage assay | IC50 = 20.99 μg/mL | 24-h | Prostate | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HepG-2 | Liver Cancer | LDH leakage assay | IC50 = 35.84 μg/mL | 24-h | Liver | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | MCF-7 | Breast Cancer | LDH leakage assay | IC50 = 45.71 μg/mL | 24-h | Breast | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HL-60 | Leukemia Cancer | MTT assay | IC50 < 40 μg/mL | 24-h | Blood | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | DU-145 | Prostrate Cancer | MTT assay | IC50 ~ 20 μg/mL | 24-h | Prostate | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | HepG-2 | Liver Cancer | MTT assay | IC50 ~ 40 μg/mL | 24-h | Liver | None | ||
| 26482932 | 2015 | Cytotoxin-I | 60 | Cyclic | L | None | Free | Free | Anticancer | Caspian cobra (Naja oxiana) venom | MCF-7 | Breast Cancer | MTT assay | IC50 < 20 μg/mL | 24-h | Breast | None | ||
| 24692446 | 2014 | NaD1 | 47 | Cyclic(C3-C47,C14-34,C20-C41,C24-C43) | L | None | None | None | Host Defense | Nicotiana alata | B16-F10 | Skin Cancer | MTT assay | IC50 = 1.5 ± 0.6 μM | 48-h | Skin | None | ||
| 24692446 | 2014 | NaD1 | 47 | Cyclic(C3-C47,C14-34,C20-C41,C24-C43) | L | None | None | None | Host Defense | Nicotiana alata | HeLa | Cervical Cancer | MTT assay | IC50 = 1.0 ± 0.1 μM | 48-h | Cervix | None | ||
| 24692446 | 2014 | NaD1 | 47 | Cyclic(C3-C47,C14-34,C20-C41,C24-C43) | L | None | None | None | Host Defense | Nicotiana alata | MM170 | Skin Cancer | MTT assay | IC50 = 2.4 ± 0.8 μM | 48-h | Skin | None | ||
| 24692446 | 2014 | NaD1 | 47 | Cyclic(C3-C47,C14-34,C20-C41,C24-C43) | L | None | None | None | Host Defense | Nicotiana alata | MCF-7 | Breast Cancer | MTT assay | IC50 = 2.0 ± 1.3 μM | 48-h | Breast | None | ||
| 24692446 | 2014 | NaD1 | 47 | Cyclic(C3-C47,C14-34,C20-C41,C24-C43) | L | None | None | None | Host Defense | Nicotiana alata | HCT-116 | Colon Cancer | MTT assay | IC50 = 4.9 ± 3.1 μM | 48-h | Colon | None | ||
| 10531277, 18957441 | 1999 | Crotamine | 42 | Not Available | L | None | Free | Free | Antibacterial | Rattlesnake venom, Crotalus durissus terrificus | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 3985614, 18957441 | 1985 | Pyrularia thionin | 47 | Not Available | L | None | Free | Free | Antibacterial | Nuts,Pyrularia pubera | Not Available | Colorectal Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 1710983, 18957441 | 1991 | Viscotoxin B | 46 | Not Available | L | None | Free | Free | Anticancer | Viscum album L | Not Available | Colorectal Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 9348108, 18957441 | 1997 | Viscotoxin A2 | 46 | Not Available | L | None | Free | Free | Antibacterial | Viscum album L | Not Available | Colorectal Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 9348108, 18957441 | 1997 | Viscotoxin 1-PS | 46 | Not Available | L | None | Free | Free | Antibacterial | Viscum album L | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 9348108, 18957441 | 1997 | Viscotoxin A1 | 46 | Not Available | L | None | Free | Free | Antibacterial | Viscum album L | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 9348108, 18957441 | 1997 | Viscotoxin C1 | 46 | Not Available | L | None | Free | Free | Antibacterial | The Asiatic Viscum album ssp Coloratum ohwi | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 5719166, 18957441 | 1968 | Viscotoxin A3 | 46 | Not Available | L | None | Free | Free | Antibacterial | The European mistletoe, Viscum album | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 15700822, 18957441 | 2004 | Viscotoxin B2 | 46 | Not Available | L | None | Free | Free | Anticancer | Viscum coloratum (Kom.) Nakai | Not Available | Breast Cancer | Not Available | Not Available | Not Available | Not Available | None | ||
| 6385903, 18957441 | 1984 | Microcin E492 | 84 | Not Available | L | None | Free | Free | Antibacterial | Klebsiella pneumoniaeRYC492 | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 35.2 % Cell viability at 100 µM | 72-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 41.1 % Cell viability at 75 µM | 72-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 49.7 % Cell viability at 50 µM | 72-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 63.3 % Cell viability at 25 µM | 72-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 72.1 % Cell viability at 12.5 µM | 72-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 48.6 % Cell viability at 100 µM | 48-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 54.3 % Cell viability at 100 µM | 48-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 62.8 % Cell viability at 75 µM | 48-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 75.6 % Cell viability at 50 µM | 48-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 87.3 % Cell viability at 25 µM | 48-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 54.2 % Cell viability at 100 µM | 24-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 71.5 % Cell viability at 75 µM | 24-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 76.3% Cell viability at 50 µM | 24-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 84.1% Cell viability at 25 µM | 24-h | Liver | None | ||
| 20383464 | 2010 | Ceropin | 63 | Linear | L | None | Free | Free | Antimicrobial | Musca domestica | BEL-7402 | Liver Cancer | Trypan blue assay | 91.8% Cell viability at 12.5 µM | 24-h | Liver | None | ||
| None | 2022 | Sample Peptide 5 from US011339203B2 | 41 | Linear | L | None | Amidation | Free | Anticancer | Synthetic | CAKI-2 | Renal Cancer | CCK-8 assay | Cell Viability = 77.6% at 25 μM | 48-h | Kidney | US011339203B2 |